Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Stereotactic Body Radiotherapy
Christelle BouchartiD, Oier Azurmendi SenariD, Julie NaveziD, Laurine VersetiD, Anaïs Boisson, Matthieu HeiniD, Kosta StosiciD, Eric QuertinmontiD, Vjola Tafciu, Shulin ZhaoiD, Léo Mas, Nicky D’HaeneiD, Dirk Van GesteliD, Luigi MorettiiD, Ilse RoomaniD, Vincent DetoursiD, Jean‐Baptiste BachetiD, Pieter DemetteriD, Karen E Willard-GalloiD, Rémy NicolleiD, Tatjana ArsenijeviciD, Jean‐Luc Van LaethemiD
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest tumors with slow progress in systemic therapies due to its peculiar and resistant tumor microenvironment. Inclusion of isotoxic high-dose stereotactic body radiation therapy (iHD-SBRT) into a total neoadjuvant strategy (TNT) is promising for the treatment of localized PDAC. However, the histo-molecular effects of iHD-SBRT are still poorly explored. In this study, we have shown that TNT, associating FOLFIRINOX [FFX] followed by iHD-SBRT, leads to significant and long-lasting remodeling of PDAC, affecting its stromal, metabolic, and molecular features. Contrary to FFX alone, TNT is able to enrich tumors with Classical and Inactive stromal signatures associated with better prognosis. Furthermore, iHD-SBRT seems capable to counteract several of the detrimental modulatory effects induced by FFX such as Epithelial-to-Mesenchymal Transition or angiogenesis. Additionally, we identified inflammatory cancer-associated fibroblasts signatures as an important prognostic factor. This work provides new rationale to sequentially combine FFX with iHD-SBRT and suggests new pathways that can be targeted in combination with a TNT. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=139 SRC="FIGDIR/small/591890v1_ufig1.gif" ALT="Figure 1"> View larger version (80K): org.highwire.dtl.DTLVardef@155da78org.highwire.dtl.DTLVardef@17a1ab7org.highwire.dtl.DTLVardef@16fe522org.highwire.dtl.DTLVardef@12c5870_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Improving SBRT by re-wiring immunosuppressive neutrophils in murine pancreatic ductal adenocarcinoma
Joseph D. Murphy, Gary Hannon, … Scott A. Gerber·International Journal of Radiation Oncology*Biology*PhysicsPeer-reviewed·Jul 2, 2025
- Neoadjuvant chemotherapy induces transient, regimen-specific immune stromal reprogramming in pancreatic ductal adenocarcinoma
Elahe Minaei, Dezerae Cox, … Kara L. Vine·bioRxiv·Sep 11, 2026
- Spatial Conformation of Pancreatic Cancer Is Associated with Disease Recurrence after Curative-Intent Total Neoadjuvant Therapy
Luis Humberto Cisneros, Merih Deniz Toruner, … Ryan Michael Carr·bioRxiv·Nov 3, 2025
- Pulsed Field Ablation Enables Stromal Manipulation and Tumor Reduction in Pancreatic Ductal Adenocarcinoma
MacKenzie V. Demmel, Lincoln N. Strickland, … Jennifer M. Bailey·bioRxiv·Oct 7, 2026
- Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer
Kendelle Joan Murphy, Cecilia R. Chambers, … Paul Timpson·bioRxiv·Jul 23, 2026
- Single-nucleus and spatial transcriptomics of archival pancreatic cancer reveals multi-compartment reprogramming after neoadjuvant treatment
William L. Hwang, Karthik A. Jagadeesh, … Aviv Regev·bioRxiv·Aug 25, 2020